Home
Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Today’s Highlights July 26, 2023

Merck and Moderna Inc Announcement

Merck (MRK) and Moderna Inc (MRNA . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
July 26, 2023

Other Articles